

1 **Caregiver’s Decision to Report Adverse Drug Reactions among Children Receiving**
2 **Seasonal Malaria Chemoprevention in Ghana**

3 Abdul Gafaru Mohammed¹, Dora Dadzie¹, George Adu Asumah¹, Isaac Adomako¹, Joel Jeffrey
4 Idun-Acquah¹, Paul Boateng¹, Nana Yaw Peprah¹, Keziah L. Malm¹

5
6 ¹National Malaria Elimination Programme, Ghana Health Service, Accra, Ghana

7
8
9 Corresponding author: Abdul Gafaru Mohammed

10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Abstract**

25 **Introduction:** The antimalarial medicines used in Seasonal Malaria Chemoprevention (SMC)
26 campaigns are generally well-tolerated but adverse drug reactions (ADRs) can occur. Monitoring,
27 reporting, and prompt management of ADRs is essential to build and maintain trust in SMC
28 campaigns in the implementing communities. The caregiver's decision to report ADRs represents
29 a critical issue at the intersection of public health, child welfare, and pharmacovigilance. As SMC
30 campaigns continue to expand, it is imperative to understand and address the factors influencing
31 caregivers' decisions to report ADRs.

32 **Methods:** A mixed methods cross-sectional study involving questionnaire administration, focus
33 group discussions, and review of children's health records was employed to collect data from
34 caregivers of children aged 3-59 months in the Northern, North-East, and Savanna regions of
35 Ghana. A systematic random sample of 679 caregivers was recruited for the study across three
36 regions. Data including ADR occurrence, maternal and child characteristics was collected from
37 selected caregivers in their homes. Logistic regression was performed for associations between
38 caregiver's reports of ADRs and caregiver characteristics.

39 **Results:** About 49.5% (336/679) of caregivers mentioned the occurrence of ADRs in children after
40 receiving SMC medication. The commonly cited ADR was diarrhea (34.7%, 116/336). Only
41 16.9% (57/336) of caregivers reported ADRs to the health workers at the time of occurrence. After
42 adjusting for confounders, increasing age of child (aOR=1.04, 95%CI:1.008-1.065), receiving
43 education on ADR reporting (aOR=4.03, 95%CI:4.366-6.119), education on management of mild
44 ADRs (aOR=4.43, 95%CI:2.094-9.808) and having a means of reaching health personnel
45 (aOR=1.56, 95%CI:1.202-2.037) increased the odds of ADR reporting while increasing age of

46 caregivers (aOR=0.92, 95%CI:0.883-0.966) and being married (aOR=0.17, 95%CI:0.149-0.183)
47 decreased the odds of reporting ADRs among the caregivers studied.

48 **Conclusion:** Less than 20% of caregivers whose children experienced ADRs after receiving SMC
49 medication reported the incident. Caregiver education on ADRs and its management and means
50 of reaching the health team were modifiable factors that influenced caregiver ADR reporting.

51

52 **Keywords:** Malaria, Seasonal Malaria Chemoprevention, Adverse Drug Reaction, Ghana, ADR,
53 SMC

54

55 **Introduction**

56 To complement ongoing malaria control efforts, including vector control measures, prompt
57 diagnosis of suspected malaria, and treatment of confirmed cases with antimalarial medicines, the
58 WHO in 2012 recommended seasonal malaria chemoprevention (SMC) for the control of malaria
59 among children under age 5 (1–3) in areas where malaria transmission is seasonal. SMC is defined
60 as “the intermittent administration of full treatment of an anti-malarial medicine during the malaria
61 season to prevent malarial illness and to maintain therapeutic drug concentrations in the blood
62 throughout the greatest malarial risk (4). Ghana adopted this preventive intervention in 2013 (2)
63 for children aged 3-59 months. SMC began with a pilot from July 2015 to October 2015 in the
64 Lawra district of the Upper West region, followed by a full-scale implementation in the year 2016
65 across all districts of the Upper West and Upper East regions (2). Currently, the intervention has
66 been implemented in 69 districts located in Northern, North-East, Savannah, Upper East, Upper
67 West, Bono East, and Oti regions of Ghana.

68 The success of SMC depends on the efficacy and safety of the amodiaquine plus sulfadoxine-
69 pyrimethamine (AQ+SP) (5,6). Countries implementing SMC have adopted various
70 pharmacovigilance reporting measures either passive or active for reporting possible adverse drug
71 reactions (7,8). Ghana adopted a passive pharmacovigilance reporting process for SMC-related
72 ADRs whose success largely depends on the caregivers of the children receiving the therapy.
73 SMC administration has been reported to be associated with various adverse reactions among
74 children receiving the therapy (9–11). The most commonly reported side effects are diarrhea,
75 abdominal pain, body weakness and vomiting (8). These ADRs have been reported by caregivers
76 to mostly occur within the second or third day after administering the therapy. ADR reporting rate
77 has been reported to be low among health workers and caregivers of children receiving the therapy
78 (12–14). In a study conducted in northern Nigeria, out of seven states implementing SMC, only
79 two states reported ADRs from the exercise (11).

80 Reporting adverse drug reactions by caregivers of children receiving SMC has been reported to be
81 influenced by various factors. These factors include poor knowledge, not being aware of the term
82 ADR, single marital status, lower education level, and difficulty accessing public clinics for
83 medical services (15).

84 There is currently a paucity of data on the reporting of ADRs among caregivers of children
85 receiving SMC and the factors that influence their decision to report. Studies conducted on ADRs
86 among children receiving SMC in the West African sub-region focus on the healthcare staff
87 providing the service with none exploring the problem among caregivers (11). With the passive
88 pharmacovigilance reporting approach adopted for SMC ADRs in Ghana, it is important to assess
89 the rate of ADR reporting among caregivers of children under the therapy and also the factors that
90 influence their decision to report ADRs. This study was therefore conducted to assess the factors

91 that influence the decision of caregivers to report ADRs when they occur among children receiving
92 SMC in Ghana.

93

94 **Methods**

95 **Study design**

96 This was a mixed methods cross-sectional study among caregivers of children between 6 – 59
97 months in Ghana. A semi-structured questionnaire, data abstraction tool and FGD guide were used
98 to collect data on the characteristics of children and their caregivers, the uptake of SMC, the
99 occurrences of ADRs, and its reporting.

100 **Study setting**

101 The study was conducted in Ghana. Ghana is located in West Africa with an estimated 31 million
102 people, 16 administrative regions, and 261 districts. The country shares boundaries with Togo,
103 Burkina Faso, Ivory Coast, and the Gulf of Guinea. Following the WHO recommendation of SMC
104 as an intervention, Ghana adopted it in 2013 and included it in the NSP for implementation to
105 ensure that malaria morbidity and mortality among children under five years are reduced to zero.
106 Malaria cases among children under five have seen a drastic decline in the implementing regions
107 since the intervention was rolled out. The intervention is usually given during the transmission
108 period (rainy season). In 2021 and 2022, Ghana Health Service (GHS) through the National
109 Malaria Elimination Programme supported 7 regions (Northern, North-East, Savannah, Upper
110 East, Upper West, Bono East, and Oti) to implement the SMC in 72 districts. The study was
111 conducted in three of the seven regions. These regions included Savanna, Northern, and North East
112 Regions. In 2022 and 2023, each of these regions received four cycles of seasonal malaria
113 chemoprevention within the rainy season. The rainy season ranged from May – September.

114 **Study population**

115 The study included all caregivers of children aged 3 – 59 months in the Northern, Savanna, and
116 North East Region. in Ghana. Caregivers of children between 3 – 59 months of age, who have
117 lived in the selected districts for at least one year were included in the study. Caregivers of children
118 aged 3 – 59 months in whom the use of SMC is contraindicated were excluded from the study.
119 Also, caregivers of children who missed the 2023 SMC dosing campaign were excluded from the
120 study.

121 **Sample size estimation**

122 Using $Z =$ indicator for a confidence level (1.96 for 95% confidence level), $n =$ minimum sample
123 size, De is the design effect, the ratio between the variance from the cluster design to the variance
124 that would be obtained from a simple random sampling, Z (1.96), P (66.5%) (16) and e (5%) is the
125 margin of error allowed. We estimated a minimum sample size using the formula $n = [De \times Z^2 \times p$
126 $(1-p)]/e^2$. $n = [2 \times (1.96)^2 \times 0.67 \times 0.33]/(0.05)^2 = 679$.

127 **Sampling process**

128 A multistage cluster sampling approach was used to sample caregivers for the study. The first stage
129 involved the simple random sampling of three (3) regions out of the 7 regions implementing SMC.
130 Followed by sampling of 4 districts from each of the three (3) selected regions. A stratified random
131 sampling approach was then used to sample two communities from each of the districts. Two strata
132 were formed for each district, stratum A (list of rural communities in the district) and stratum B
133 (list of urban communities in the district). One community was randomly selected from each of
134 these strata making up two communities from each district. A probability proportionate to size
135 sampling approach using the number of children registered for the 2022 SMC in each of the
136 selected communities was used to determine the total number of caregivers to interview in each of

137 the communities. Finally, a systematic random sampling approach was used to recruit caregivers
138 for interviews on each day of data collection by trained research assistants.

139 **Data collection**

140 Data was collected from caregivers of children between 3 – 59 months using a pre-tested semi-
141 structured questionnaire, a focus group discussion guide, and a data abstraction tool adapted from
142 previous studies (17–19). Data was collected between October – December 2023. The
143 questionnaire was prepared and deployed on Kobo collect for data collection. The questionnaire
144 was prepared in English and interpreted into Dagare, Kasena, Frafra, Twi, Asante, Dagbani,
145 Konkomba, and Nanumba during administration. The semi-structured questionnaire elicited data
146 on children’s characteristics (age, sex, education), characteristics of their caregivers (age, sex,
147 marital status, region, residence, educational status, employment status), awareness and
148 knowledge of ADRs, and occurrence of ADRs and its reporting. The data abstraction tool was
149 used to extract data on the update of SMC and the number of doses received from the maternal
150 and child health records book.

151 Fifteen community health nurses were recruited and trained as research assistants to collect data
152 from the study participants. The research assistants were trained in the general overview of the
153 study, the sampling approach, the eligibility procedure, all sections of the questionnaire,
154 questionnaire administration, the use of data abstraction tool, participant privacy and
155 confidentiality, and their safety. The data collection tools were pre-tested among 30 caregivers in
156 Ahafo Region prior to the actual data collection. All issues observed during the pre-test were
157 rectified before the actual data collection.

158 **Data analysis**

159 The data collected was extracted from Kobo-Collect as Microsoft Excel files, cleaned, and
160 imported into R-studio for statistical analysis. The data was descriptively analyzed, and categorical
161 variables were summarized into frequencies and percentages with accompanying 95% Confidence
162 Intervals. Parametric continuous variables such as age were summarized into means and standard
163 deviations. A crude binary logistic regression analysis was performed to determine the association
164 between participants' characteristics and the decision to report ADRs. Variables with $p < 0.25$ were
165 considered statistically significant and selected for an adjusted binary logistic regression analysis.
166 At the adjusted level, the level of significance was set at 5%.

167

168 **Results**

169 **Background characteristics of caregivers and children**

170 Out of the 679 caregivers studied, majority (57.6%; 391) were rural dwellers. The median age of
171 caregivers was 29 (IQR= 25 – 33) years with most (63.5%; 431) being between 25 – 34 years old.
172 Almost half (45.8%; 311) of the caregivers were housewives or unemployed. The average age of
173 the children under the care of selected caregivers was 28 (IQR=20 – 34) months with majority
174 (52.4%; 356) of them being male (**Table 1**).

175 **Table 1: Background characteristics of caregivers and children**

Characteristics	Frequency (n = 679)	Proportion (%)
Place of residence		
Rural	391	57.58
Urban	288	42.42
Age of caregiver, median (IQR) years	29 (25 – 33)	

18 – 24	132	19.44
25 – 34	431	63.48
35+	116	17.08
Educational level		
No formal education	256	37.70
Primary	166	24.45
Secondary	172	25.33
Tertiary	85	12.52
Occupation		
Government employed	100	14.73
Unemployed or housewife	311	45.80
Trader	268	39.47
Marital status		
Married	617	90.87
Unmarried	62	9.13
Age of child [median (IQR) months]	28 (20 – 34)	
Sex of child		
Female	323	47.57
Male	356	52.43

176

177 **Individual-level characteristics of the caregivers studied**

178 More than two-thirds (70.1%; 476) of the caregivers had a health facility in their community of
 179 residence. Also, almost half (47.9%; 325) of the caregivers had no means of contacting the medical
 180 team in case of a severe adverse event (**Table 2**).

181 **Table 2: Individual-level characteristics of the caregivers studied**

Characteristics	Frequency (n = 679)	Proportion (%)
Availability of HF		
No	203	29.90

Yes	476	70.10
Received education on ADR reporting		
No	327	48.16
Yes	352	51.84
Received education on management of mild ADRs		
No	262	38.59
Yes	417	61.41
Means of contacting health workers		
No	325	47.86
Yes	354	52.14

182

183 **Occurrence of Adverse drug reactions and reporting**

184 Out of 679 caregivers studied, almost half (49.5%; 336) mentioned the occurrence of adverse drug
 185 reactions in their children following the uptake of SMC medications in the most recent SMC cycle.

186 The most common ADRs experienced were fever (44.2%; 148) and diarrhea (34.6%; 116).

187 Majority (48.4%; 162) of these ADRs occurred after 2 hours of receiving medications with (41.1%;

188 138) managing their children at home. Less than a fifth (16.9%; 57) of the caregivers reported the

189 ADRs to the nearest health facility or a medical practitioner (**Table 3**).

190 **Table 3: Occurrence of Adverse drug reactions and reporting**

Variable	Frequency (n = 679)	Proportion (%)
Adverse drug reaction (n = 679)		
Did not occur	343	50.52
Occurred	336	49.48
Type of ADR (n = 336)		
Diarrhea	116	34.63
Vomiting	96	28.57

Headache	28	8.33
Rashes	22	6.55
Fever	74	22.02
Time of occurrence (n = 335)		
Within 1	84	25.07
1 – 2 hours	89	26.57
After 2 hours	162	48.36
Action taken (n = 336)		
Visited drug store	93	27.68
Managed child at home	138	41.07
Did nothing	73	21.73
Take child to health facility	32	9.52
Reporting (n = 336)		
No	279	83.04
Yes	57	16.96

191

192 **Stratification of ADR Reporting by place of residence**

193 Overall, out of 336 children who experienced ADRs after receiving SMC medication, only 16.9
 194 (95%CI: 0.132 – 0.214) reported the occurrence. Reporting of ADRs was higher among caregivers
 195 residing in urban settings compared to their counterparts in rural settings (**Table 4**).

196 **Table 4: Stratification of ADR Reporting by place of residence**

Residence	Proportion of ADR reporting	95% CI
Rural	1.6	0.003 0.046
Urban	36.0	0.283 0.442
Overall	16.9	0.132 0.214

197

198 **Factors associated with associated with ADRs Reporting among caregivers**

199 After adjusting for the effect of confounders, age of caregivers (aOR = 0.92, 95%CI: 0.883 - 0.966)
200 marital status (aOR = 0.17, 95%CI: 0.149 - 0.183), age of child (aOR = 1.04, 95%CI: 1.008 -
201 1.065), education on ADR reporting (aOR = 4.03, 95%CI: 4.366 - 6.119) and management of mild
202 ADRs (aOR = 4.43, 95%CI: 2.094 - 9.808), and means of reaching health personnel (aOR = 1.56,
203 95%CI: 1.202 - 2.037) were factors found to be significantly associated with the reporting of ADRs
204 among the caregivers studied. Caregivers who were educated on ADR reporting had 4 times
205 increased odds of reporting adverse events when they occurred compared to those who were not
206 educated on ADR reporting (aOR = 4.03, 95%CI: 4.366 - 6.119). Also, A unit increase in the age
207 of caregivers was associated with an 8% decrease in the odds of reporting adverse events following
208 SMC in their children (aOR = 0.92, 95%CI: 0.883 - 0.966) (**Table 5**).

209

210 **Occurrence of ADRs and its reportage among caregivers**

211 *“The health worker told us the medicines will protect our children against malaria. I give the*
212 *drugs to both my children; I wasn’t informed my children may have any reactions after taking*
213 *the medicines”*. **Caregiver 4**

214 *“I noticed that my child's appetite decreased after taking the medication on the first day. He even*
215 *refused his favorite food which I prepared for him. I thought this was because he had started*
216 *growing teeth, I didn’t know the drugs could affect his appetite I would have reported to the*
217 *health facility if I knew”*. **Caregiver 6**

218 *“My child started running diarrhea, the same day the health workers came to the house to give*
219 *him the drugs, the diarrhea increased after I gave him the other one on the second day so I*
220 *didn’t even give him the last one, I was scared”*. **Caregiver 1**

221 *“The man who came to our house to give the medicine to my son told me he might vomit or have*
222 *a hot temperature or run diarrhea so I should go to the hospital if it happened. Nothing happened*
223 *on the first day but my son had a hot temperature the third day after I gave him the drugs. I gave*
224 *him paracetamol syrup I got the last time he was sick”*. **Caregiver 5**

225 *“My husband is a nurse, so when my daughter had diarrhea after taking the drugs on the second*
226 *day, I informed him, and he said maybe the diarrhea is caused by the drug so I should take her to*
227 *the health center in our area. I took her there and the health workers gave us some drugs, they*
228 *didn’t even charge us money that day”*. **Caregiver 10**

229

230 **Discussion**

231 Seasonal administration of antimalaria drug, sulphadoxine/pyrimethamine plus amodiaquine
232 (SPAQ) to children 3–59 months is a tool in the reduction of childhood malaria morbidity and
233 mortality in areas with highly seasonal malaria transmission like Northern Ghana (20). In 2023,
234 1,492,779 children in the Northern, North East, Upper West, Upper East, Bono East, and Oti
235 regions received SPAQ during the fourth round of the seasonal malaria chemoprevention
236 campaign in Ghana. Using a mixed methods approach, our study assessed the factors that influence
237 the decision of caregivers to report ADRs when they occur among children receiving SMC in
238 Ghana. Less than 17% of caregivers were found to report adverse drug reactions when they
239 occurred in this study. The reporting rate found in this study is consistent with the findings of
240 similar studies conducted in Northern Nigeria and Senegal where ADR reporting was found to be
241 abysmally low (21,22). Also, in a study assessing parental reporting of adverse drug reactions in
242 South Africa, majority (66.5%) of participants did report an ADR to a healthcare professional (23).

243 The occurrence of ADRs during SMC that go unreported or unresolved tends to affect the trust
244 caregivers have on SMC medications thereby affecting the willingness of caregivers to allow their
245 children to receive SMC medications. The ready availability of health workers or volunteers to
246 caregivers tends to increase ADR reporting. To achieve this, the National Malaria Elimination
247 Programme through the various regional and district health directorates needs to implement and
248 strengthen follow-up visits to the homes of children receiving SPAQ during SMC campaigns.

249 The commonly reported ADRs were fever, diarrhea, and vomiting. This is corroborated by the
250 findings of a similar study among young children in Northern Sahelian Ghana where diarrhea,
251 vomiting, and fever were the most experienced adverse events during the four rounds of SMC
252 administration (24). Also, in Community-Based Safety Monitoring during Seasonal Malaria
253 Chemoprevention Campaigns in Senegal, the most commonly reported symptoms were vomiting,
254 fever, and abdominal pain (21). These reported ADRs have the tendency of putting a child in a
255 dire situation if not managed properly and timely. During SMC campaigns, caregivers need to be
256 educated on the reporting of these adverse events and also first aid management of these events
257 prior to the arrival of the medical team.

258 Our study found a significant association between marital status and ADR reporting among the
259 caregivers studied. Caregivers who were unmarried had increased odds of reporting ADRs
260 compared to married caregivers. The decision-making power in Northern Ghana mostly lies with
261 husbands in marriage. Caregivers who are married mostly need to seek advice from their partners
262 before taking any health-seeking decision, this may delay or possibly impede the reporting of
263 adverse events. Unlike married caregivers, unmarried caregivers mostly have the decision-making
264 power lying with them and they can easily report ADRs when they occur without consulting
265 another person.

266 The ease of access to health personnel and healthcare facilities can influence parental reporting of
267 ADRs. Caregivers who have convenient means of reaching healthcare providers, such as through
268 telephone hotlines, online portals, or direct visits to healthcare facilities, may be more likely to
269 report adverse events. Accessibility to health personnel can facilitate timely reporting of adverse
270 events and increase the likelihood of receiving appropriate guidance on managing these events.
271 Our study found increased odds of reporting adverse events among caregivers with means of
272 reaching the health team compared to caregivers without any means of reaching the health
273 authority. To increase ADR reporting, district health directorates need to adopt a strategy where
274 volunteers share the call lines of health facilities located in the community during SMC campaigns
275 in those communities. This will facilitate ease of reporting ADRs when they occur.

276 Furthermore, education on ADR reporting was also found to increase the reporting of ADRs
277 among caregivers. This is consistent with the findings of a study among pharmacists in Egypt
278 where those who received education on adverse events reporting had an increased chance of
279 reporting events compared to those who were not educated on the reporting process (19). Similarly,
280 education on adverse events reporting was reported to increase adverse event identification and
281 reporting among nursing health professionals in a tertiary health facility in India (25). This implies
282 that increasing caregiver awareness of adverse events and its reporting process will increase the
283 number of caregivers who would report adverse events when they occur in their children during
284 SMC. Also, education on the management of mild adverse events was another factor found to be
285 significantly associated with adverse events reporting by caregivers in this study. Caregivers who
286 received education on how to manage mild or minor adverse events had increased odds of reporting
287 adverse events compared to those not educated. Health volunteers visiting homes during SMC
288 should be strengthened to provide education on ADR, management, and reporting during dosing.

289 A limitation of this study was recall bias, caregivers recalled ADRs in their children who received
290 medication in the past, and this could have led to underestimation or overestimation of ADR
291 occurrence and its reporting.

292

293 **Conclusion**

294 Less than 20% of caregivers whose children experienced ADRs after receiving SMC medication
295 reported the incident. Caregiver education on ADRs and it's management and means of reaching
296 the health team were modifiable factors that influenced the caregiver's ADR reporting.

297

298 **Acknowledgments**

299 We wish to acknowledge the research assistants and the various regional and district health
300 directorates that supported the exercise.

301

302 **Authors' contributions**

303 AGM & DD conceptualized the study and conducted data. AGM and PB analyzed the collected
304 data. GAA, IA, JJIA, NYP and KLM, drafted the initial manuscript. All authors read and approved
305 the manuscript for publication.

306

307 **Funding**

308 No funding received

309

310 **Availability of data and materials**

311 The data for this study is available in this publication.

312

313 **Declarations**

314 Ethical clearance for the study was obtained from the Ghana Health Service Ethical Review
315 Committee. Permission was sought from the various regional and district health directorates in the
316 region before the study. Written informed consent was obtained from the caregivers of children
317 recruited for the study. The data collected was devoid of personal identifiers and was used solely
318 for this study.

319

320 **Consent for publication**

321 Not applicable.

322

323 **Competing interests**

324 The authors declared no competing interests.

325

326 **References**

- 327 1. Adjei MR, Kubio C, Buamah M, Sarfo A, Suuri T, Ibrahim S, et al. Effectiveness of
328 seasonal malaria chemoprevention in reducing under-five malaria morbidity and mortality
329 in the Savannah Region, Ghana. *Ghana Med J* [Internet]. 2022 May 31 [cited 2022 Dec
330 19];56(2):64–70. Available from:
331 <https://www.ajol.info/index.php/gmj/article/view/229630>
- 332 2. Nonvignon J, Aryeetey GC, Issah S, Ansah P, Malm KL, Ofofu W, et al. Cost-
333 effectiveness of seasonal malaria chemoprevention in upper west region of Ghana. *Malar J*
334 [Internet]. 2016 Jul 16 [cited 2022 Dec 19];15(1):1–13. Available from:
335 <https://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1418-z>
- 336 3. Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M.
337 Seasonal malaria chemoprevention in an area of extended seasonal transmission in
338 Ashanti, Ghana: an individually randomised clinical trial. *Tropical Medicine &*
339 *International Health* [Internet]. 2016 Feb 1 [cited 2022 Dec 19];21(2):224–35. Available
340 from: <https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.12642>
- 341 4. Adjei MR, Kubio C, Buamah M, Sarfo A, Suuri T, Ibrahim S, et al. Effectiveness of
342 seasonal malaria chemoprevention in reducing under-five malaria morbidity and mortality
343 in the Savannah Region, Ghana. *Ghana Med J*. 2022 May 31;56(2):64–70.
- 344 5. Kirakoya-Samadoulougou F, De Brouwere V, Fokam AF, Ouédraogo M, Yé Y. Assessing
345 the effect of seasonal malaria chemoprevention on malaria burden among children under
346 5 years in Burkina Faso. *Malar J*. 2022;21(1):1–10.
- 347 6. Cairns ME, Sagara I, Zongo I, Kuepfer I, Thera I, Nikiema F, et al. Evaluation of seasonal
348 malaria chemoprevention in two areas of intense seasonal malaria transmission:

- 349 Secondary analysis of a household-randomised, placebo-controlled trial in Houndé
350 District, Burkina Faso and Bougouni District, Mali. *PLoS Med.* 2020;17(8):1–23.
- 351 7. NDiaye JL, Cissé B, Ba EH, Gomis JF, Ndour CT, Molez JF, et al. Safety of seasonal
352 malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine when
353 delivered to children under 10 years of age by district health services in Senegal: Results
354 from a stepped-wedge cluster randomized trial. *PLoS One.* 2016;11(10):1–15.
- 355 8. Koko DC, Maazou A, Jackou H, Eddis C. Analysis of attitudes and practices influencing
356 adherence to seasonal malaria chemoprevention in children under 5 years of age in the
357 Dosso Region of Niger. *Malar J.* 2022;21(1):1–10.
- 358 9. Chatio S, Ansah NA, Awuni DA, Oduro A, Ansah PO. Community acceptability of
359 Seasonal Malaria Chemoprevention of morbidity and mortality in young children: A
360 qualitative study in the Upper West Region of Ghana. *PLoS One.* 2019;14(5):1–12.
- 361 10. Thera MA, Kone AK, Tangara B, Diarra E, Niare S, Dembele A, et al. School-aged
362 children based seasonal malaria chemoprevention using artesunate-amodiaquine in Mali.
363 *Parasite Epidemiol Control.* 2018;3(2):96–105.
- 364 11. Rotimi K, Aiden J, Dabes C, Maduka K, Oguiche D, Itiola AJ, et al. Pharmacovigilance
365 reporting during seasonal malaria chemoprevention campaign: Findings from northern
366 Nigeria. *Sci Afr.* 2022;17:e01283.
- 367 12. Rotimi K, Aiden J, Dabes C, Maduka K, Oguiche D, Itiola AJ, et al. Pharmacovigilance
368 reporting during seasonal malaria chemoprevention campaign: Findings from northern
369 Nigeria. *Sci Afr.* 2022;17:e01283.

- 370 13. Diawara SI, Konaté D, Kayentao K, Mihigo J, Shaffer JG, Sangare M, et al. Effect of
371 seasonal malaria chemoprevention in children between 5 and 9 years old in Kita and
372 Bafoulabe districts, Mali. *Parasite Epidemiol Control*. 2022;18(April).
- 373 14. Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M.
374 Seasonal malaria chemoprevention in an area of extended seasonal transmission in
375 Ashanti, Ghana: an individually randomised clinical trial. *Tropical Medicine &*
376 *International Health*. 2016 Feb 1;21(2):224–35.
- 377 15. Pillay S, Mulubwa M, Viljoen M. Parental reporting of adverse drug reactions in South
378 Africa: An online survey. *Afr J Prim Health Care Fam Med*. 2021;13(1):1–8.
- 379 16. Pillay S, Mulubwa M, Viljoen M. Parental reporting of adverse drug reactions in South
380 Africa: An online survey. *Afr J Prim Health Care Fam Med*. 2021;13(1):1–8.
- 381 17. Gurmesa LT, Dedefo MG. Factors affecting adverse drug reaction reporting of healthcare
382 professionals and their knowledge, attitude, and practice towards ADR reporting in
383 Nekemte Town, West Ethiopia. *Biomed Res Int*. 2016;2016:5–8.
- 384 18. Al Dweik R, Stacey D, Kohen D, Yaya S. Factors affecting patient reporting of adverse
385 drug reactions: a systematic review. *Br J Clin Pharmacol*. 2017 Apr;83(4):875–83.
- 386 19. Bahlol M, Bushell M, Khojah HMJ, Dewey RS. Spontaneous adverse drug reaction
387 reporting by community pharmacists: preparedness and barriers. *Saudi Pharmaceutical*
388 *Journal*. 2022 Jul 1;30(7):1052–9.
- 389 20. NMCP. 1 | Page. 2021.

- 390 21. Ndiaye JLA, Diallo I, NDiaye Y, Kouevidjin E, Aw I, Tairou F, et al. Evaluation of Two
391 Strategies for Community-Based Safety Monitoring during Seasonal Malaria
392 Chemoprevention Campaigns in Senegal, Compared with the National Spontaneous
393 Reporting System. *Pharmaceut Med*. 2018 Jun 1;32(3):189–200.
- 394 22. Rotimi K, Aiden J, Dabes C, Maduka K, Oguche D, Itiola AJ, et al. Pharmacovigilance
395 reporting during seasonal malaria chemoprevention campaign: Findings from northern
396 Nigeria. *Sci Afr*. 2022 Sep 1;17.
- 397 23. Pillay S, Mulubwa M, Viljoen M. Parental reporting of adverse drug reactions in South
398 Africa: An online survey. *Afr J Prim Health Care Fam Med*. 2021;13(1):1–8.
- 399 24. Chatio S, Ansah NA, Awuni DA, Oduro A, Ansah PO. Community acceptability of
400 Seasonal Malaria Chemoprevention of morbidity and mortality in young children: A
401 qualitative study in the Upper West Region of Ghana. *PLoS One*. 2019;14(5):1–12.
- 402 25. SONOWAL S, K DESAI C, R PANCHAL J. IMPACT OF CERTAIN EDUCATIONAL
403 INTERVENTIONS ON ADVERSE DRUG REACTION REPORTING BY NURSING
404 HEALTH PROFESSIONALS AT A TERTIARY CARE HOSPITAL. *Asian Journal of*
405 *Pharmaceutical and Clinical Research*. 2020 Apr 20;175–80.
- 406
407
408
409
410
411

Table 5: Factors associated with associated with ADRs Reporting among Caregivers

Variables	ADR Reporting		cOR (95%CI)	aOR (95%CI)
	Unreported n (%)	Reported n (%)		
Age of caregiver, median (IQR) years			0.93 (0.898 0.971)	0.92 (0.883 0.966)
Educational level				
No formal education	17 (84.52)	13 (15.48)	1.00	1.00
Primary	75 (83.33)	15 (16.67)	1.09 (0.748 1.594)	1.03 (0.779 1.369)
Secondary	98 (83.05)	20 (16.95)	1.11 (0.388 3.195)	1.11 (0.478 2.587)
Tertiary	35 (79.55)	9 (20.45)	1.40 (0.788 2.501)	1.51 (0.843 2.738)
Occupation				
Government employed	29 (50.88)	28 (49.12)	1.00	1.00
Unemployed or housewife	107 (88.43)	14 (11.57)	0.14 (0.043 0.421)	0.10 (0.043 0.236)
Private employed/Trader	143 (90.51)	15 (9.49)	0.11 (0.047 0.250)	0.06 (0.022 0.143)
Marital status				
Married	254 (87.59)	36 (12.41)	0.17 (0.147 0.193)	0.17 (0.149 0.183)
Unmarried	25 (54.35)	21 (45.65)	1.00	1.00
Age of child median (IQR) months			1.03 (1.015 1.052)	1.04 (1.008 1.065)
Availability of HF				
No	127 (88.81)	16 (11.19)	1.00	1.00
Yes	152 (78.76)	41 (21.24)	2.14 (0.589 7.774)	0.83 (0.632 1.105)

Education on ADRs reporting				
No	187 (92.57)	15 (7.43)	1.00	1.00
Yes	92 (68.66)	42 (31.34)	5.69 (3.368 9.616)	4.03 (4.366 6.119)
Education on management of mild ADRs				
No	132 (93.62)	9 (6.38)	1.00	1.00
Yes	147 (75.38)	48 (24.62)	4.78 (0.736 31.171)	4.43 (2.094 9.808)
Means of reaching health workers				
No	125 (83.89)	24 (16.11)	1.00	1.00
Yes	154 (82.35)	33 (17.65)	1.12 (1.035 1.202)	1.56 (1.202 2.037)